Advertisement
UK markets close in 5 hours 5 minutes

  • FTSE 100

    8,090.71
    +45.90 (+0.57%)
     

  • FTSE 250

    19,804.43
    +4.71 (+0.02%)
     

  • AIM

    754.92
    +0.05 (+0.01%)
     

  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2439
    -0.0014 (-0.11%)
     

  • Bitcoin GBP

    53,351.63
    +170.92 (+0.32%)
     

  • CMC Crypto 200

    1,432.41
    +8.31 (+0.58%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.96
    -0.40 (-0.48%)
     

  • GOLD FUTURES

    2,330.60
    -11.50 (-0.49%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,176.78
    +39.13 (+0.22%)
     

  • CAC 40

    8,133.32
    +27.54 (+0.34%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca's Lynparza fails in gastric cancer combination test

Reuters - UK Focus

LONDON, May 18 (Reuters) - AstraZeneca (NYSE: AZN - news) 's recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.

The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings.

AstraZeneca said it was disappointed, but noted this particular trial was unusual in using a low dose and combining Lynparza with a standard chemotherapy.

The company has high hopes for Lynparza, which is central to its goal of building a portfolio of compounds targeting DNA damage response (DDR (NYSE: DDR - news) ) mechanisms in cancer cells. (Reporting by Ben Hirschler; Editing by Mark Potter)